GRAIL has generated enormous innovations in oncology care over the past 2 decades and will continue this trend through exploring 1 of oncology’s biggest opportunities, early detection of cancer, said Joshua Ofman, MD, chief of Corporate Strategy and External Affairs at GRAIL Inc.
GRAIL has generated enormous innovations in oncology care over the past 2 decades, and will continue this trend through exploring 1 of oncology’s biggest opportunities, early detection of cancer, said Joshua Ofman, MD, chief of Corporate Strategy and External Affairs at GRAIL Inc.
Transcript
How does GRAIL delineate what works and what doesn’t work when it comes to formulating strategies for improving oncology care?
We've made enormous progress in oncology over the last 2 decades. We've developed novel therapeutics, innovative approaches, and molecular diagnostics are now playing an increasing role in cancer. As we've looked at the opportunities to improve cancer care, early detection of cancer seems to be 1 of the biggest opportunities. So, as we've strategically thought about this new technology that GRAIL’s developed using circulating DNA and evaluating an individual's DNA, that's circulating in the blood to look for cancer signals, the opportunity we saw before us was in early cancer detection. Too many cancers are simply detected too late, where outcomes are poor and that's causing an enormous burden in this country that's both human and economic around cancer. So, by early detection, and providing something simple like a blood test for the broad population of screening eligible patients, we think this can be a game changer for how we could approach cancer control and early cancer detection.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More